Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.
Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity. A total of 44 patients with glioblastoma with gross macroscopic tumor removal were included. MRIs were performed at various times postoperatively (within 24 hours, 1 week, 1 month, 2 months, 3 months, 6 months, 9 months, and 1 year). MR protocols included a T2-, diffusion-weighted, and T1-weighted sequences with and without intravenous administration of gadolinium. On T1, the wafers change from their initial hypointense to an isointense appearance after a period during which they appear to be hypointense, with a hyperintense rim most prominent less than 1 month postoperatively. On T2 they change from a hypointense to an isointense appearance. Restricted diffusivity reshaping the silhouette of the wafer's surface at the rim of the resection cavity can be found as early as day 1 postoperatively; however, 1 month after implantation, they all show areas of restricted diffusion, which may remain up to 1 year. Contrast enhancement at the rim of the resection cavity can already be found at day 1 postoperatively, with a peak shortly after 1 month after surgery. These changes can easily be mistaken for an abscess and hamper the early differentiation between residual tumor tissue and normal postoperative changes. However, early changes in either appearance do not predict overall survival or the progression free interval.
Diagnostic and Interventional Neuroradiology, University Hospital of Basel, Basel, Switzerland. ulmer@email.com
Stephan
S
Ulmer
Klara
K
Spalek
Arya
A
Nabavi
Susan
S
Schultka
H Maximillian
HM
Mehdorn
Santosh
S
Kesari
Lutz
L
Dörner
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D001672:Biocompatible Materials; D001921:Brain / Q000473:pathology*; D001922:Brain Abscess / Q000175:diagnosis; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D002330:Carmustine / Q000008:administration & dosage; D003652:Decanoic Acids; D003951:Diagnostic Errors; D038524:Diffusion Magnetic Resonance Imaging; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging; D011091:Polyesters; D013997:Time Factors
D018906:Antineoplastic Agents, Alkylating; D001672:Biocompatible Materials; D003652:Decanoic Acids; D011091:Polyesters; C055401:decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; D002330:Carmustine